State Street Corp Gamida Cell Ltd. Transaction History

State Street Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.73 - $4.29 $1,150 - $2,852	-665 Reduced 0.89%	73,987 $131,000
Q1 2022 May 16, 2022	BUY	$2.22 - $4.47 $7,374 - $14,849	3,322 Added 4.66%	74,652 $310,000
Q4 2021 Feb 14, 2022	BUY	$2.2 - $4.46 $2,890 - $5,860	1,314 Added 1.88%	71,330 $181,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $6.44 $166,219 - $278,040	43,174 Added 160.84%	70,016 $274,000
Q2 2021 Aug 16, 2021	SELL	$5.85 - $8.33 $3,685 - $5,247	-630 Reduced 2.29%	26,842 $172,000

Q1 2021 May 17, 2021	SELL	$7.8 - $12.43 $23 - $37	-3 Reduced 0.01%	27,472 $222,000
Q4 2020 Feb 16, 2021	SELL	$4.07 - $11.0 $3,589 - $9,702	-882 Reduced 3.11%	27,475 $231,000
Q3 2020 Nov 10, 2020	BUY	$3.93 - $4.59 $111,443 - $130,158	28,357 New	28,357 $118,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.